Baillie Gifford - ADAPTIMMUNE THERAPEUTICS PLC ownership

ADAPTIMMUNE THERAPEUTICS PLC's ticker is ADAP and the CUSIP is 00653A107. A total of 68 filers reported holding ADAPTIMMUNE THERAPEUTICS PLC in Q4 2022. The put-call ratio across all filers is 0.23 and the average weighting 0.1%.

Quarter-by-quarter ownership
Baillie Gifford ownership history of ADAPTIMMUNE THERAPEUTICS PLC
ValueSharesWeighting
Q3 2023$13,374,980
-15.8%
17,147,409
-0.2%
0.01%
-14.3%
Q2 2023$15,887,926
-14.8%
17,176,135
+0.4%
0.01%
-17.6%
Q1 2023$18,652,082
-25.6%
17,112,002
-0.3%
0.02%
-34.6%
Q4 2022$25,068,111
+59.0%
17,169,939
+17.1%
0.03%
+62.5%
Q3 2022$15,764,000
-39.5%
14,664,936
-4.3%
0.02%
-40.7%
Q2 2022$26,046,000
-17.8%
15,321,346
-0.4%
0.03%
+22.7%
Q1 2022$31,684,000
-38.6%
15,380,538
+11.8%
0.02%
-21.4%
Q4 2021$51,587,000
-22.2%
13,756,352
+7.3%
0.03%
-20.0%
Q3 2021$66,306,000
+33.1%
12,824,980
+9.6%
0.04%
+45.8%
Q2 2021$49,828,000
-18.2%
11,696,919
+2.0%
0.02%
-29.4%
Q1 2021$60,892,000
+9.1%
11,467,517
+10.7%
0.03%
+9.7%
Q4 2020$55,828,000
-1.2%
10,357,780
+46.3%
0.03%
-20.5%
Q3 2020$56,482,000
+6.7%
7,078,063
+33.8%
0.04%
-2.5%
Q2 2020$52,950,000
+347.1%
5,289,669
+21.5%
0.04%
+207.7%
Q1 2020$11,843,000
+130.2%
4,354,023
+1.6%
0.01%
+160.0%
Q4 2019$5,145,000
-18.2%
4,287,545
+2.9%
0.01%
-28.6%
Q3 2019$6,289,000
-62.2%
4,164,807
+0.5%
0.01%
-61.1%
Q2 2019$16,658,000
+0.9%
4,143,840
+7.9%
0.02%0.0%
Q1 2019$16,508,000
-22.4%
3,839,190
+3.8%
0.02%
-35.7%
Q4 2018$21,272,000
-54.1%
3,699,521
+8.2%
0.03%
-44.0%
Q3 2018$46,343,000
+28.7%
3,417,627
+12.7%
0.05%
+28.2%
Q2 2018$36,005,000
+25.0%
3,033,261
+18.2%
0.04%
+14.7%
Q1 2018$28,810,000
+124.6%
2,565,409
+33.6%
0.03%
+112.5%
Q4 2017$12,829,000
+13.6%
1,920,593
+39.2%
0.02%
+14.3%
Q3 2017$11,297,000
+90.2%
1,379,304
+4.2%
0.01%
+75.0%
Q2 2017$5,941,000
+17.1%
1,323,308
+43.7%
0.01%
+14.3%
Q1 2017$5,075,000
+36.1%
920,9840.0%0.01%
+16.7%
Q4 2016$3,730,000
-42.6%
920,9840.0%0.01%
-40.0%
Q3 2016$6,493,000
+85.4%
920,984
+114.3%
0.01%
+66.7%
Q2 2016$3,502,000
+0.3%
429,7000.0%0.01%0.0%
Q1 2016$3,493,000429,7000.01%
Other shareholders
ADAPTIMMUNE THERAPEUTICS PLC shareholders Q4 2022
NameSharesValueWeighting ↓
MPM ASSET MANAGEMENT LLC 6,287,101$4,903,9392.63%
Syncona Portfolio Ltd 1,377,294$1,074,2891.60%
MPM BioImpact LLC 5,095,912$3,974,8111.06%
NEA Management Company, LLC 17,079,778$13,322,2271.03%
TANG CAPITAL MANAGEMENT LLC 5,166,954$4,030,2240.57%
PFM Health Sciences, LP 10,423,135$8,130,0450.38%
Matrix Capital Management Company, LP 38,974,185$30,399,8640.36%
Long Focus Capital Management, LLC 10,963,158$8,551,2630.31%
Acuitas Investments, LLC 479,764$374,2160.22%
Endurant Capital Management LP 311,944$243,3160.22%
View complete list of ADAPTIMMUNE THERAPEUTICS PLC shareholders